SWOG clinical trial number
S2424CD
A Randomized Controlled Trial of an Intervention called Algorithm-Enabled Patients Activated in Cancer Care through Teams (A-PACT) to Improve Goals of Care Communication for People with Cancer
Open
Phase
Accrual
0%
Abbreviated Title
Testing an educational program to improve goals of care conversations between patients and their care teams
Status Notes
Activation 06/01/2026
Activated
06/01/2026
Participants
Limited: SWOG NCORP Cancer Care Delivery Research (CCDR) Components
Research committees
Cancer Care Delivery
Eligibility Criteria Expand/Collapse
5.1 Patient Participant Disease Related Criteria
a. Participants must have a diagnosis of a solid tumor malignancy of any stage.
b. Participants must be identified as high risk, defined as having 6 month mortality estimate from machine learning (ML) algorithm >= 20% (0.20).
c. Participants must not be receiving or have pre-existing plans to enter hospice care at the time of study registration.
5.2 Patient Participant Prior/Concurrent Therapy Criteria
a. Participant must be actively receiving or planning to receive systemic anti-cancer therapy (defined as any oral, injection, or intravenous therapy against cancer) within 3 months after registration.
NOTE: This includes chemotherapy (conventional or cytotoxic chemotherapy), hormone therapy, targeted therapy, and immunotherapy.
NOTE: Participants are allowed to be co-enrolled on other clinical trials including trials using investigational agents.
5.3 Patient Participant Clinical/Laboratory Criteria
a. Participants must be >= 18 years of age at the time of study enrollment.
b. Participants must be able to speak English or Spanish. The intervention is delivered via oral communication in English or Spanish.
c. Participants who can complete Patient Reported Outcome (PRO) questionnaires in English or Spanish must be willing to 1) complete PROs at all scheduled assessments (per Section 15.3); and 2) complete the pre-registration (baseline) PRO forms within 14 days prior to registration.
d. Participants must be able to provide a valid telephone number for the purpose of being contacted by the lay health worker.
a. Participants must have a diagnosis of a solid tumor malignancy of any stage.
b. Participants must be identified as high risk, defined as having 6 month mortality estimate from machine learning (ML) algorithm >= 20% (0.20).
c. Participants must not be receiving or have pre-existing plans to enter hospice care at the time of study registration.
5.2 Patient Participant Prior/Concurrent Therapy Criteria
a. Participant must be actively receiving or planning to receive systemic anti-cancer therapy (defined as any oral, injection, or intravenous therapy against cancer) within 3 months after registration.
NOTE: This includes chemotherapy (conventional or cytotoxic chemotherapy), hormone therapy, targeted therapy, and immunotherapy.
NOTE: Participants are allowed to be co-enrolled on other clinical trials including trials using investigational agents.
5.3 Patient Participant Clinical/Laboratory Criteria
a. Participants must be >= 18 years of age at the time of study enrollment.
b. Participants must be able to speak English or Spanish. The intervention is delivered via oral communication in English or Spanish.
c. Participants who can complete Patient Reported Outcome (PRO) questionnaires in English or Spanish must be willing to 1) complete PROs at all scheduled assessments (per Section 15.3); and 2) complete the pre-registration (baseline) PRO forms within 14 days prior to registration.
d. Participants must be able to provide a valid telephone number for the purpose of being contacted by the lay health worker.
Other Clinical Trials
SWOG Clinical Trial Number
S2424CD
A Randomized Controlled Trial of an Intervention called Algorithm-Enabled Patients Activated in Cancer Care through Teams (A-PACT) to Improve Goals of Care Communication for People with Cancer
Research Committee(s)
Cancer Care Delivery
Activated
06/01/2026
Accrual
0%
Open
Phase
SWOG Clinical Trial Number
S2417CD
A Pragmatic Randomized Controlled Trial to Evaluate the Effectiveness of an Intervention called Current Together After Cancer (CTAC) to Promote Guideline-Concordant Colorectal Cancer Surveillance
Research Committee(s)
Cancer Care Delivery
Gastrointestinal Cancer
Activated
08/04/2025
Accrual
12%
Open
Phase
SWOG Clinical Trial Number
S1703
Randomized trial comparing overall survival of patients monitored with serum tumor marker directed disease monitoring (STMDDM) versus usual care in patients with metastatic hormone receptor positive breast cancer
Research Committee(s)
Cancer Care Delivery
Breast Cancer
Activated
07/16/2018
Accrual
92%
Open
Phase